Here We Grow!

TRxADE Health Inc. is growing! Our office have relocated to: 1115 Gunn Hwy, Odessa, FL 33556.

We are excited about our growth and look forward to many more years of bringing technology and innovation to the pharmaceutical marketplace.

The “Lock-In” Pharmacy Approach to Rx Drug Abuse

The “Lock-In” Pharmacy Approach to Rx Drug Abuse

By Kevin Schweers

A proposal to restrict certain Medicare beneficiaries to use only a dedicated, “lock-in” pharmacy for their controlled substances is now a part of legislation introduced by two House lawmakers.

House Ways and Means Health Subcommittee Chair Kevin Brady (R-Texas) and Ranking Member Jim McDermott (D-Wash.) recently proposed the Protecting the Integrity of Medicare Act (PIMA). The broad bill is comprised of a range of proposals intended to reduce Medicare fraud, waste and abuse. Its features include the “lock-in” pharmacy idea.

Read Full Article Here:


Suren Ajjarapu TRxADE TRXD

TRxADE Health, Inc. (OTCQB: TRXD) CEO Interview Series

Posted by:  Wall Street Analyzer

View the post and listen to the interview here:

TRxADE Health Investors

National Health Expenditure Projections, 2013–23: Faster Growth Expected With Expanded Coverage And Improving Economy

National Health Expenditure Projections, 2013–23: Faster Growth Expected With Expanded Coverage And Improving Economy

Posted by:

In 2013 health spending growth is expected to have remained slow, at 3.6 percent, as a result of the sluggish economic recovery, the effects of sequestration, and continued increases in private health insurance cost-sharing requirements. The combined effects of the Affordable Care Act’s coverage expansions, faster economic growth, and population aging are expected to fuel health spending growth this year and thereafter (5.6 percent in 2014 and 6.0 percent per year for 2015–23). However, the average rate of increase through 2023 is projected to be slower than the 7.2 percent average growth experienced during 1990–2008. Because health spending is projected to grow 1.1 percentage points faster than the average economic growth during 2013–23, the health share of the gross domestic product is expected to rise from 17.2 percent in 2012 to 19.3 percent in 2023.

Read Full Article Here:


TRxADE National Business

Fracking Development Could Strengthen U.S. Manufacturing Exports

Fracking Development Could Strengthen U.S. Manufacturing Exports

September 1, 2014 April Nowicki
In less than three months, a panel of economic experts from the Initiative on Global Markets at the University Of Chicago Booth School Of Business increased their confidence rating on how fracking technology could stimulate growth of U.S. merchandise exports.The economists help provide context about important public policy issues by expressing whether they agreed or disagreed on statements regarding issues.In May, the panel responded to this statement: “New technology for fracking natural gas, by lowering energy costs in the United States, will make U.S. industrial firms more cost competitive and thus significantly stimulate the growth of US merchandise exports.”

Weighted by confidence, the experts responded with opinions split nearly right down the middle. Thirty-four percent agreed with the statement, and 34 percent did not. Eighteen percent were uncertain, 9 percent strongly agreed and 5 percent strongly disagreed.

Out of 32 experts on the panel who responded, eight noted that while lower prices might or will increase U.S. exports, they did not expect the rate of growth to be substantial. Four experts also wrote that additional fracking development could have environmental impacts that could lead to broader negative economic impacts.

“Energy costs are set largely in the world market,” said Janet Currie, professor of economics at Princeton University. “Moreover, environmental degradation could make areas less competitive in the long run.”

In August, the panel again responded to the same statement. Responses were not received from all the same experts as responded to the May survey.

The previously split opinions had shifted in favor of agreement with the statement: 59 percent of the experts who responded either agreed or strongly agreed with the statement. Nineteen percent disagreed, 8 percent strongly disagreed and 15 percent were uncertain.

Some experts changed their answers: Currie and Alan Auerbach, professor of economics and law at Berkeley University, switched responses from “Disagree” to “Uncertain.” Marianne Bertrand, professor of economics at University of Chicago, switched from “Uncertain” to “Agree,” with a low confidence rating of 3, while Raj Chetty, professor of economics at Harvard University, changed his response from “Agree” to “Uncertain.” Some noted that while costs may fall initially, the long-term effects were not clear.

“I agree that energy cost should fall, which will increase U.S. competitiveness,” said Oliver Hart, professor of economics at Harvard University. “The effects on growth are more subtle, and harder to predict.”

Read full article here:

Wockhardt’s earnings devastated by FDA bans

Wockhardt’s earnings devastated by FDA bans

Problems with data manipulation, sanitation undercut sales in key markets
August 12, 2014 | By
With FDA bans in place on two plants, India’s Wockhardt saw its profits slip in the first part of this year. But with access to its largest market still severely curtailed, Wockhardt has been unable to get its financial footing and profits went crashing in its last quarter, off 94%.

Wockhardt reported Tuesday that its April-June net profit was 199.5 million rupees ($3.26 million), compared with 3.23 billion rupees ($52.9 million) a year earlier, Reuters reported. Net sales fell 27% to 9.91 billion rupees ($162 million) and were off 60% in the U.S., the company said in its earnings report.

The drugmaker had two of its manufacturing plants in India banned last year from exporting to the U.S. after inspectors found that it had been manipulating its testing data and passing for sale drugs that were not up to specs. The agency has since followed up with an intensive review of Wockhardt’s Morton Grove plant near Chicago, which was helping the drugmaker prop up its U.S. sales, citing it for many of the same kinds of problems.